Genedata Biologics Will Be Featured at Protein Engineering Summit – PEGS 2011

Share Article

Biologics R&D advances with increasing industry adoption of Genedata Biologics™

Genedata Biologics makes biologics discovery more efficient and can easily save millions of R&D dollars

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced it will showcase Genedata Biologics at the Seventh Annual PEGS. Genedata Biologics, a first-in-class biologics data management and analysis platform, helps to advance biologics research and development. Recently released, it has already been adopted by several leading pharmaceutical and biotech companies. The software solution will be featured at PEGS in a Bayer Healthcare Pharmaceuticals presentation on Engineering Antibodies. It will also be showcased in a number of PEGS poster sessions spanning diverse applications in protein engineering, optimization and expression as well as specialized use cases such as engineering of bispecific antibodies. PEGS, the leading protein engineering summit, will be held at the Sheraton Boston Hotel, May 9 – 13.

“Biopharmaceuticals is the fastest growing market segment in the pharmaceutical industry; however, the discovery and development process for biologics molecules is extremely complex, labor intensive, and costly,” said Dr. Othmar Pfannes, CEO of Genedata. “With Genedata Biologics we provide the first integrated platform supporting the entire biologics R&D process. The system allows the collection of all relevant experimental data generated along the biologics R&D process and makes these data available to all involved laboratories and project managers. Therefore, data and material handovers from lab-to-lab are greatly facilitated, and decision making is put onto a solid foundation based on experimental data. This helps to make our customers’ overall biologics discovery and development processes more efficient and ensures consistently high quality standards across different laboratories.”

Genedata Biologics Saves Millions in R&D Dollars    
“Genedata Biologics makes biologics discovery more efficient and can easily save millions of R&D dollars,” continued Pfannes. Based on more than four years of development in close collaboration with international pharmaceutical and biotechnology customers, Genedata Biologics is an off-the-shelve software platform that allows the provisioning of focused solutions for specific parts of biologics R&D with modules that address:

  • Antibody Screening for antibody selection and screening, including tools for sample management and plate logistics, integrated sequence and assay analysis, and molecule registration; to address company-specific requirements for phage-display, SLAM, or hybridoma data.
  • Protein Engineering for supporting protein engineering and optimization workflows, including automated construct and plasmid design, antibody reformatting and protein engineering activities including germlining and humanization.
  • Protein Production for molecular biology, cell line development, protein expression, and protein purification processes, including tools for vector design, sample management and analytics data management.

Based on a comprehensive biologics registration infrastructure, the system comes with built-in engines to ensure uniqueness of biologics molecules and materials – for both proteins and antibodies; and classical as well as next-generation format molecules. These capabilities advance high-quality standards and avoid duplicated efforts. Providing easy data access for all biologics molecules and materials, the system provides flexible tools for naming, association, searching, retrieving, analyzing, and reporting.

With an Oracle®-based database infrastructure and a web-based front-end, Genedata Biologic’s open design allows seamless interfacing and integration with existing corporate IT infrastructures and laboratory instruments. The system is equipped with a default configuration that minimizes set-up and customization efforts, and lowers implementation costs. Genedata Biologics can be easily configured to support corporate-specific variants of biologics R&D workflows such as handling of proprietary libraries, workflows, or molecule formats.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead, and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, Genedata Expressionist®, Genedata Analyst™, Genedata Selector™, and Genedata Biologics™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany, and the US.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Allison Kurz
+41 61 511 8459
Email >

Jackie Thrasivoulos
+1 508 881 3109
Email >
Visit website